We claim:

1. A process for preparing a compound of Formula (I):



(I)

from a benzazepine-phenol of Formula (II):



(II),

wherein the benzazepine-phenol of Formula (II) is prepared by a process comprising converting a compound of Formula (III):



(III)

to a compound of Formula (IV):



(IV);

wherein:

R^P is H or a suitable phenol protecting group;

R^3 and R^4 are the same or different and are each independently H or a carboxylic acid ester protecting group;

R^2 is R^7, C_1-C_4 alkyl, C_1-C_4 haloalkyl, A-C_0-C_4 alkyl-, A-C_2-C_4 alkenyl-, A-C_2-C_4 alkynyl-, A-C_3-C_4 oxoalkenyl-, A-C_3-C_4 oxoalkynyl-, A-C_0-C_4 aminoalkyl-, A-C_3-C_4 aminoalkenyl-, A-C_3-C_4 aminoalkynyl-, optionally substituted by any accessible combination of one or more of R^{10} or R^7;

A is H, C_3-C_6 cycloalkyl, Het or Ar;

R^7 is $-COR^8$, $-COCR'_2R^9$, $-C(S)R^8$, $-S(O)_mOR'$, $-S(O)_mNR'R''$, $-PO(OR')$, $-PO(OR')_2$, $-NO_2$, or tetrazolyl;

each R^8 independently is $-OR'$, $-NR'R''$, $-NR'SO_2R'$, $-NR'OR'$, or $-OCR'_2CO(O)R'$;

R^9 is $-OR'$, $-CN$, $-S(O)_rR'$, $-S(O)_mNR'_2$, $-C(O)R'$, $C(O)NR'_2$, or $-CO_2R'$;

R^{10} is H, halo, $-OR^{11}$, $-CN$, $-NR'R^{11}$, $-NO_2$, $-CF_3$, $CF_3S(O)_r-$, $-CO_2R'$, $-CONR'_2$, A-C_0-C_6 alkyl-, A-C_1-C_6 oxoalkyl-, A-C_2-C_6 alkenyl-, A-C_2-C_6 alkynyl-, A- C_0-C_6 alkyloxy-, A-C_0-C_6 alkylamino- or A-C_0-C_6 alkyl-$S(O)_r$-;

R^{11} is R', -C(O)R', $-C(O)NR'_2$, -C(O)OR', $-S(O)_mR'$, or $-S(O)_mNR'_2$;

R^1 is


,

,

,

,

,

,

,

, or

;

W is $-(CHR^8)_n$-U- $(CHR^8)_b$-;

U is absent or CO, CR^g_2, $C(=CR^g_2)$, $S(O)_k$, O, NR^g, CR^gOR^g, $CR^g(OR^k)CR^g_2$, $CR^g_2CR^g(OR^k)$, $C(O)CR^g_2$, $CR^g_2C(O)$, $CONR^i$, NR^iCO, OC(O), C(O)O, C(S)O, OC(S), $C(S)NR^g$, $NR^gC(S)$, $S(O)_2NR^g$, $NR^gS(O)_2$ N=N, NR^gNR^g, $NR^gCR^g_2$, $CR^g_2NR^g$, CR^g_2O OCR^g_2, C≡C or CR^g=CR^g;

G is NR^e, S or O;

R^g is H, C_1-C_6 alkyl, Het-C_0-C_6 alkyl, C_3-C_7 cycloalkyl-C_0-C_6 alkyl or Ar-C_0-C_6 alkyl;

R^k is R^g, -C(O)R^g, or -C(O)OR^f;

R^i is H, C_1-C_6 alkyl, Het-C_0-C_6 alkyl, C_3-C_7 cycloalkyl-C_0-C_6 alkyl, Ar-C_0-C_6 alkyl, or C_1-C_6 alkyl substituted by one to three groups chosen from halogen, CN, NR^g_2, OR^g, SR^g, CO_2R^g, and $CON(R^g)_2$;

R^g is H, C_1-C_6 alkyl or Ar-C_0-C_6 alkyl;

R^e is H, C_1-C_6 alkyl, Ar-C_0-C_6 alkyl, Het-C_0-C_6 alkyl, C_3-C_7 cycloalkyl-C_0-C_6 alkyl, or $(CH_2)_kCO_2R^g$;

R^b and R^c are independently selected from H, C_1-C_6 alkyl, Ar-C_0-C_6 alkyl, Het-C_0-C_6 alkyl, or C_3-C_6 cycloalkyl-C_0-C_6 alkyl, halogen, CF_3, OR^f, $S(O)_kR^f$, COR^f, NO_2, $N(R^f)_2$, $CO(NR^f)_2$, $CH_2N(R^f)_2$, or R^b and R^c are joined together to form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF_3, C_1-C_4 alkyl, OR^f, $S(O)_kR^f$, COR^f, CO_2R^f, OH, NO_2, $N(R^f)_2$, $CO(NR^f)_2$, and $CH_2N(R^f)_2$; or methylenedioxy;

Q^1, Q^2, Q^3 and Q^4 are independently N or C-R^y, provided that no more than one of Q^1, Q^2, Q^3 and Q^4 is N;

R' is H, C_1-C_6 alkyl, Ar-C_0-C_6 alkyl or C_3-C_6 cycloalkyl-C_0-C_6 alkyl;

R" is R', -C(O)R' or -C(O)OR';

R"' is H, C_1-C_6 alkyl, Ar-C_0-C_6 alkyl, Het-C_0-C_6 alkyl, or C_3-C_6 cycloalkyl-C_0-C_6 alkyl, halogen, CF_3, OR^f, $S(O)_kR^f$, COR^f, NO_2, $N(R^f)_2$, $CO(NR^f)_2$, $CH_2N(R^f)_2$;

R^y is H, halo, -OR^g, -SR^g, -CN, -NR^gR^k, -NO_2, -CF_3, $CF_3S(O)_r$-, -CO_2R^g, -COR^g or -$CONR^g_2$, or C_1-C_6 alkyl optionally substituted by halo, -OR^g, -SR^g, -CN, -NR^gR", -NO_2, -CF_3, R'$S(O)_r$-, -CO_2R^g, -COR^g or -$CONR^g_2$;

a is 0, 1 or 2;

b is 0, 1 or 2;

k is 0, 1 or 2;

m is 1 or 2;

r is 0, 1 or 2;

s is 0, 1 or 2;

u is 0 or 1; and

v is 0 or 1.

2. A process according to claim 1, comprising preparing a compound of Formula (I-S):



(I-S)

from a benzazepine-phenol of Formula (II-S):



(II-S),

wherein the benzazepine-phenol of Formula (II-S) is prepared by a process comprising converting a compound of Formula (III):



(III)

to a compound of Formula (IV-S):



(IV-S).

3. A process according to claim 1, further comprising a process for preparing the compound of Formula (II) comprising the steps of:

1) treating a compound having Formula (a)



(a)

wherein R^P is H or a suitable phenol protecting group and X is halogen, $-OSO_2F$, or $-OSO_2CF_3$,

with a compound having the formula:



to form a compound of Formula (b)



(b);

2) converting the compound of Formula (b) to a compound of Formula (c);



(c)

wherein R^5 and $R^{5'}$ are C_1-C_4 alkyl or R^5 and $R^{5'}$, taken together with the atoms to which they are attached form a saturated 5- or 6-membered heterocyclic ring and Z and Z' are independently selected from O, NH or NCH_3;

3) converting the compound of Formula (c) to a compound of Formula (d):



(d);

4) converting the compound of Formula (d) to a compound of Formula (e)



(e);

5) converting the compound of Formula (e) to a compound of Formula (f)



(f); and

6) converting the compound of Formula (f) to a compound of Formula (II).

4. A process according to claim 1, further comprising a process for preparing the compound of Formula (II) comprising the steps of:

1) converting 3-hydroxybenzaldehyde to a compound of Formula (aa)



(aa);

2) treating the compound of Formula (aa) with itaconic acid to form a compound of Formula (bb):



(bb);

3) converting the compound of Formula (bb) to a compound of Formula (cc)



(cc),

where R^5 and $R^{5'}$ are C_1-C_4 alkyl or R^5 and $R^{5'}$, taken together with the atoms to which they are attached form a saturated 5- or 6-membered heterocyclic ring;

4) converting the compound of Formula (cc) to a compound of Formula (dd)


(dd);

5) converting the compound of Formula (dd) to a compound of Formula (ee)


(ee); and

6) converting the compound of Formula (ee) to a compound of Formula (II).

5. A process according to claim 2, further comprising a process for preparing the compound of Formula (II-S) comprising the steps of:

1) converting the compound having the formula:


;

wherein R^5 and $R^{5'}$ are C_1-C_4 alkyl or R^5 and $R^{5'}$, taken together with the atoms to which they are attached form a saturated 5- or 6-membered heterocyclic ring and Z and Z' are independently selected from O, NH or NCH_3, to a compound having the formula:


;

2) converting the compound formed in step 1) into a compound having the formula:



3) converting the compound formed in step 2) into the compound having the formula:



; and

4) converting the compound formed in step 3) into the compound of Formula (II-S).

6. A process according to claim 2, further comprising a process for preparing the compound of Formula (II-S) comprising the steps of:

1) converting the compound having the formula:



,

wherein R^5 and $R^{5'}$ are C_1-C_4 alkyl or R^5 and $R^{5'}$, taken together with the atoms to which they are attached form a saturated 5- or 6-membered heterocyclic ring, into a compound having the formula:



;

2) converting the compound formed in step 1) into a compound having the formula:



; and

3) converting the compound formed in step 2) into the compound of Formula (II-S).

7. A process according to claim 1, further comprising a process for preparing the compound of Formula (I) having the formula:



comprising the steps of:

1) converting 2-amino-6-methylpyridine into a compound having the formula:



,

wherein R^P is a suitable amino protecting group;

2) converting the compound formed in step 1) to a compound having the formula:



;

3) converting the compound formed in step 2) to a compound having the formula:



,

wherein R^6 is H or an alkyl carboxylic acid ester protecting group;

4) converting the compound formed in step 3) to a compound having the formula:



;

5) treating the compound formed in step 4) with a compound having the formula:



to form a compound having the formula:



; and

6) converting the compound formed in step 5) to the compound of Formula I.

8. A process according to claim 1, further comprising a process for preparing the compound of Formula (I) having the formula:



comprising the steps of:

1) converting 2-amino-6-methylpyridine into a compound having the Formula:



;

2) converting the compound formed in step 1) to a compound having the formula:



;

3) converting the compound formed in step 2) to a compound having the formula:



;

4) converting the compound formed in step 3) to a compound having the formula:



;

5) treating the compound formed in step 4) with a compound having the formula:



to form a compound having the formula:



; and

6) converting the compound formed in step 5) to the compound of Formula (I).

9. A process according to claim 1, further comprising a process for preparing the compound of Formula (I) having the formula:



comprising the steps of:

1) converting a compound having the formula:



wherein X is halogen or $-OSO_2CF_3$, to a compound having the formula:


;

2) converting the compound formed in step 1) into a compound having the formula:


,

wherein X' is halogen, $-OSO_2CH_3$, $-OSO_2CF_3$, $-OSO_2$(phenyl), or $-OSO_2$(p-tolyl);

3) treating the compound formed in step 2) with a compound having the formula:



to form a compound having the formula:


; and

4) converting the compound formed in step 3) into the compound of Formula (I).

10. A process according to claim 1, further comprising a process for preparing the compound of Formula (I) having the formula:



comprising the steps of:

1) converting 2-chloropyrdine, N-oxide to a compound having the formula:



;

2) converting the compound formed in step 1) into a compound having the formula:



;

3) treating the compound formed in step 2) with a compound having the formula:



to form a compound having the formula:



; and

4) converting the compound formed in step 3) into the compound of Formula (I).

11. A process according to any one of claims 1-7 or 9, wherein R^3 is H, C_1-C_6 alkyl or phenyl-C_1-C_4 alkyl-, wherein the phenyl moiety is unsubstituted or substituted by one or more substituents selected from ortho and para substituents selected from chloro, bromo, nitro, methoxy and methyl.

12. A process according to any one of claims 1-7 or 9, wherein R^3 is H or C_1-C_4 alkyl.

13. A process according to any one of claims 1-7 or 9, wherein R^3 is C_1-C_4 alkyl.

14. A process according to any one of claims 1-7 or 9, wherein R^3 is methyl.

15. A process according to any one of claims 1-6, wherein R^4 is H, C_1-C_6 alkyl or phenyl-C_1-C_4 alkyl-, wherein the phenyl moiety is unsubstituted or substituted by one or more substituents selected from ortho and para substituents selected from chloro, bromo, nitro, methoxy and methyl.

16. A process according to any one of claims 1-6, wherein R^4 is H or C_1-C_4 alkyl.

17. A process according to any one of claims 1-6, wherein R^4 is H.

18. A compound having the formula:



,

wherein:

R^P is H or a suitable phenol protecting group;

R^4 is H or a carboxylic acid ester protecting group;

R^5 and $R^{5'}$ are C_1-C_4 alkyl or R^5 and $R^{5'}$, taken together with the atoms to which they are attached form a saturated 5- or 6-membered heterocyclic ring and Z and Z' are independently selected from O, NH or NCH_3;

or a pharmaceutically acceptable salt or solvate thereof.

19. A compound according to claim 18, wherein R^4 is H, C_1-C_6 alkyl or phenyl-C_1-C_4 alkyl-, wherein the phenyl moiety is unsubstituted or substituted by one or more substituents selected from ortho and para substituents selected from chloro, bromo, nitro, methoxy and methyl.

20. A compound according to claim 18, wherein R^4 is H or C_1-C_4 alkyl.

21. A compound according to claim 18, wherein R^4 is H.

22. A compound having the formula:



wherein::

R^P is H or a suitable phenol protecting group;

R^3 is H or a carboxylic acid ester protecting group;

R^5 and $R^{5'}$ are C_1-C_4 alkyl or R^5 and $R^{5'}$, taken together with the atoms to which they are attached form a saturated 5- or 6-membered heterocyclic ring and Z and Z' are independently selected from O, NH or NCH_3;

or a pharmaceutically acceptable salt or solvate thereof.

23. A compound according to claim 22, wherein R^3 is H, C_1-C_6 alkyl or phenyl-C_1-C_4 alkyl-, wherein the phenyl moiety is unsubstituted or substituted by one or more substituents selected from ortho and para substituents selected from chloro, bromo, nitro,. methoxy and methyl.

24. A compound according to claim 22, wherein R^3 is H or C_1-C_4 alkyl.

25. A compound according to claim 22, wherein R^3 is C_1-C_4 alkyl.

26. A compound according to claim 22, wherein R^3 is methyl.

27. A compound according to any one of claims 18-26, wherein R^P is H.

28. A compound according to any one of claims 18-27, wherein Z and Z' are both O.

29. A compound according to any one of claims 18-28, wherein R^5 and $R^{5'}$ are C_1-C_4 alkyl.

30. A compound according to any one of claims 18-29, wherein R^5 and $R^{5'}$ are methyl.

31. A compound:

8-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-1,2,4,5-tetrahydro-2-benzazepine-4-acetic acid,

S-(-)-8-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-1,2,4,5-tetrahydro-2-benzazepine-4-acetic acid,

2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-1H-2-benzazepine-4-acetic acid, or

(S)-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-1H-2-benzazepine-4-acetic acid.

32. A compound:

methyl 2, 3, 4, 5-tetrahydro-8-hydroxy-3-oxo-2-(2,2,2-trifluoroethyl)-1H-2-benzazepine-4-acetate,

(S)-methyl 2, 3, 4, 5-tetrahydro-8-hydroxy-3-oxo-2-(2,2,2-trifluoroethyl)-1H-2-benzazepine-4-acetate,

2-[(2-formyl-4-hydroxyphenyl)methylidene]succinic acid, 2-carboxyl-4-[(2-formyldimethylacetal-4-hydroxyphenyl)] butyric acid, bis(dicyclohexylamine) salt,

(S)-2-carboxyl-4-[(2-formyldimethylacetal-4-hydroxyphenyl)] butyric acid, bis(dicyclohexylamine) salt,

dimethyl 2-[(2-formyl-4-hydroxyphenyl)methyl]butanedioate, or

dimethyl (2S)-2-[(2-formyl-4-hydroxyphenyl)methyl]butanedioate.